ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C14H18N4O3
CAS番号:
分子量:
290.32
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
625127
製品名
トリメトプリム, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
SMILES string
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC
InChI key
IEDVJHCEMCRBQM-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
trimethoprim
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
類似した製品をお探しですか？ 訪問 製品比較ガイド
Application
主に抗菌剤として使用されています。ジヒドロ葉酸レダクタ-ゼに対するインヒビタ-で、原核生物細胞の酵素に対して選択的です。
Trimethoprim USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
Also, for use with USP monographs such as:
- Trimethoprim Tablets
- Trimethoprim Sulfate
- Sulfamethoxazole and Trimethoprim Tablets
- Sulfamethoxazole and Trimethoprim Injection
- Sulfamethoxazole and Trimethoprim Oral Suspension
- Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution
General description
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Repr. 2
保管分類
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
名称等を表示すべき危険物及び有害物
ishl_indicated
名称等を通知すべき危険物及び有害物
ishl_notified
1692505-300MG:
jan
E Van Duijkeren et al.
Journal of veterinary pharmacology and therapeutics, 17(1), 64-73 (1994-02-01)
The indications for use, side-effects, and pharmacokinetic parameters of trimethoprim, sulfonamides and their combinations in the horse are reviewed. Trimethoprim/sulfonamide (TMPS) combinations are used for the treatment of various diseases caused by gram-positive and gram-negative bacteria, including infections of the
Concentration evolution of pharmaceutically active compounds in raw urban and industrial wastewater.
Dolores Camacho-Muñoz et al.
Chemosphere, 111, 70-79 (2014-07-07)
The distribution of pharmaceutically active compounds in the environment has been reported in several works in which wastewater treatment plants have been identified as the main source of these compounds to the environment. The concentrations of these compounds in influent
Karin Tegmark Wisell et al.
The Journal of antimicrobial chemotherapy, 62(1), 35-40 (2008-04-15)
The lack of oral treatment alternatives for enterococcal urinary tract infections (UTIs) has led to a renewed interest in trimethoprim. Enterococci can incorporate exogenously produced folates and thereby reverse the effect of trimethoprim. Although a large proportion of enterococci appear
Christine Manyando et al.
PloS one, 9(5), e96017-e96017 (2014-05-17)
Antibiotic therapy during pregnancy may be beneficial and impacts positively on the reduction of adverse pregnancy outcomes. No studies have been done so far on the effects of daily Co-trimoxazole (CTX) prophylaxis on birth outcomes. A phase 3b randomized trial
O Sköld
Veterinary research, 32(3-4), 261-273 (2001-07-04)
Sulfonamides and trimethoprim have been used for many decades as efficient and inexpensive antibacterial agents for animals and man. Resistance to both has, however, spread extensively and rapidly. This is mainly due to the horizontal spread of resistance genes, expressing
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）